Logo image of NOVN

NOVAN INC (NOVN) Stock Fundamental Analysis

NASDAQ:NOVN - Nasdaq - US66988N2053 - Common Stock - Currency: USD

0.0941  -0.03 (-24.84%)

After market: 0.0894 0 (-4.99%)

Fundamental Rating

2

NOVN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of NOVN have multiple concerns. NOVN is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NOVN has reported negative net income.
NOVN had a negative operating cash flow in the past year.
NOVN had negative earnings in each of the past 5 years.
NOVN had a negative operating cash flow in each of the past 5 years.
NOVN Yearly Net Income VS EBIT VS OCF VS FCFNOVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M -50M

1.2 Ratios

NOVN has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NOVN Yearly ROA, ROE, ROICNOVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 1K 2K

1.3 Margins

NOVN has a Gross Margin of 66.06%. This is in the better half of the industry: NOVN outperforms 73.24% of its industry peers.
NOVN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NOVN Yearly Profit, Operating, Gross MarginsNOVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K -1.5K

More info and screens

0

2. Health

2.1 Basic Checks

NOVN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NOVN has more shares outstanding
NOVN has a worse debt/assets ratio than last year.
NOVN Yearly Shares OutstandingNOVN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M
NOVN Yearly Total Debt VS Total AssetsNOVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

2.2 Solvency

NOVN has an Altman-Z score of -6.93. This is a bad value and indicates that NOVN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of NOVN (-6.93) is worse than 69.95% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.93
ROIC/WACCN/A
WACC8.45%
NOVN Yearly LT Debt VS Equity VS FCFNOVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M -40M

2.3 Liquidity

NOVN has a Current Ratio of 0.74. This is a bad value and indicates that NOVN is not financially healthy enough and could expect problems in meeting its short term obligations.
NOVN's Current ratio of 0.74 is on the low side compared to the rest of the industry. NOVN is outperformed by 91.08% of its industry peers.
NOVN has a Quick Ratio of 0.74. This is a bad value and indicates that NOVN is not financially healthy enough and could expect problems in meeting its short term obligations.
NOVN has a Quick ratio of 0.72. This is amonst the worse of the industry: NOVN underperforms 86.85% of its industry peers.
Industry RankSector Rank
Current Ratio 0.74
Quick Ratio 0.72
NOVN Yearly Current Assets VS Current LiabilitesNOVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

More info and screens

7

3. Growth

3.1 Past

NOVN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.76%, which is quite impressive.
NOVN shows a strong growth in Revenue. In the last year, the Revenue has grown by 512.74%.
Measured over the past years, NOVN shows a very strong growth in Revenue. The Revenue has been growing by 61.73% on average per year.
EPS 1Y (TTM)21.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.94%
Revenue 1Y (TTM)512.74%
Revenue growth 3Y69.07%
Revenue growth 5Y61.73%
Sales Q2Q%64.21%

3.2 Future

Based on estimates for the next years, NOVN will show a very strong growth in Earnings Per Share. The EPS will grow by 23.25% on average per year.
The Revenue is expected to grow by 62.45% on average over the next years. This is a very strong growth
EPS Next Y78.75%
EPS Next 2Y44.82%
EPS Next 3Y29.1%
EPS Next 5Y23.25%
Revenue Next Year19.34%
Revenue Next 2Y95.98%
Revenue Next 3Y75.61%
Revenue Next 5Y62.45%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
NOVN Yearly Revenue VS EstimatesNOVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
NOVN Yearly EPS VS EstimatesNOVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80 -100

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

NOVN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 0.58, the valuation of NOVN can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NOVN indicates a rather cheap valuation: NOVN is cheaper than 100.00% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 37.64, NOVN is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 0.58
NOVN Price Earnings VS Forward Price EarningsNOVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NOVN Per share dataNOVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

NOVN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NOVN's earnings are expected to grow with 29.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.82%
EPS Next 3Y29.1%

More info and screens

0

5. Dividend

5.1 Amount

NOVN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NOVAN INC

NASDAQ:NOVN (7/25/2023, 8:00:02 PM)

After market: 0.0894 0 (-4.99%)

0.0941

-0.03 (-24.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-15 2023-05-15/bmo
Earnings (Next)08-09 2023-08-09/bmo
Inst Owners0.1%
Inst Owner Change-98.64%
Ins Owners20.94%
Ins Owner Change0%
Market Cap2.64M
Analysts82.86
Price Target15.81 (16701.28%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.14%
Min EPS beat(2)-65.44%
Max EPS beat(2)71.72%
EPS beat(4)2
Avg EPS beat(4)5.66%
Min EPS beat(4)-65.44%
Max EPS beat(4)71.72%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)9.01%
Min Revenue beat(2)-51.38%
Max Revenue beat(2)69.4%
Revenue beat(4)1
Avg Revenue beat(4)-1.57%
Min Revenue beat(4)-51.38%
Max Revenue beat(4)69.4%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)43.52%
PT rev (3m)24%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.87%
EPS NY rev (1m)49.28%
EPS NY rev (3m)49.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.42%
Revenue NY rev (1m)-12.59%
Revenue NY rev (3m)-12.59%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.58
P/S 0.11
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.51
EYN/A
EPS(NY)0.16
Fwd EY173.43%
FCF(TTM)-1.4
FCFYN/A
OCF(TTM)-1.28
OCFYN/A
SpS0.89
BVpS-0.1
TBVpS-1.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.06%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 97.74%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.74
Quick Ratio 0.72
Altman-Z -6.93
F-Score3
WACC8.45%
ROIC/WACCN/A
Cap/Depr(3y)946.74%
Cap/Depr(5y)585.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.94%
EPS Next Y78.75%
EPS Next 2Y44.82%
EPS Next 3Y29.1%
EPS Next 5Y23.25%
Revenue 1Y (TTM)512.74%
Revenue growth 3Y69.07%
Revenue growth 5Y61.73%
Sales Q2Q%64.21%
Revenue Next Year19.34%
Revenue Next 2Y95.98%
Revenue Next 3Y75.61%
Revenue Next 5Y62.45%
EBIT growth 1Y-10.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-17.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.42%
OCF growth 3YN/A
OCF growth 5YN/A